with at least one blood pressure trait in stage 1 analyses (P < 0.05/43 ~0.001) (Supplementary Table 3 ). Twenty-six of these SNPs reached experiment-wide significance (P < 3.4 × 10 −7 ). Conditional analysis did not identify any new independent variants at any of these previously identified loci [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .
The 15 newly associated variants (P < 3.4 × 10 −7 ; Supplementary Table 1) and 62 additional variants (P < 1 × 10 −5 for at least one blood pressure phenotype; Supplementary Table 2 Among the top variants at the 31 loci, 13 were missense ( Table 1) . In stage 2 analyses restricted to EA samples (Supplementary Table 4 ), all newly identified associations in EA samples meeting the significance threshold were also statistically significant in meta-analysis combining samples from all ancestry groups (Supplementary Table 5) , with the exception of rs1925153 in COL21A1. In addition, all of the variants except for the four that were nominated for follow-up on the basis of PP (SBP minus DBP) showed concordant directions of effect for SBP and DBP (Supplementary Table 6 ).
Three of the 31 new significant SNPs were low frequency (MAF = 0.01-0.05). These SNPs encode nonsynonymous substitutions in the genes NPR1 (rs35479618), SVEP1 (rs111245230), and PTPMT1 (rs11537751). NPR1 encodes natriuretic peptide receptor 1 and has been reported to be associated with blood pressure regulation in animal models 17, 18 but not previously in humans; SVEP1 and PTPMT1 are new blood pressure-associated genes. The minor alleles of all three SNPs were associated with increased blood pressure and had larger absolute effects on blood pressure than the alleles of any of the newly identified common variants. For example, each minor allele of rs35479618 was associated with an increase of 0.85 mm Hg in SBP in the follow-up samples as compared with a maximum absolute difference (per minor allele) among the new common variants of 0.43 mm Hg in SBP (for rs8068318 in TBX2; Supplementary Table 5) .
Of the 28 newly identified common variants for blood pressure, 14 were genome-wide significant in previous GWAS of lipid levels 19 , immunological disease [20] [21] [22] , diabetes [23] [24] [25] , kidney function 26 , age at menarche 27 , resting heart rate 28 , waist-hip ratio 29 , and homocysteine concentration 30 but not blood pressure ( Table 2 and Supplementary  Table 7 ). Six additional variants were reported for several phenotypes (Table 2) in previous candidate gene studies, patent filings, or GWAS, but their P values were not specified or did not reach the genome-wide significance level [31] [32] [33] [34] [35] . By contrast, the remaining eight variants were missense SNPs that have not been reported in the NHGRI GWAS catalog for any trait ( Table 2 ). Several genes in Table 2 contain multiple variants showing distinct allelic roles. HOXA3 and NOS3 harbor variants rs17428471 (HOXA3) 12 and rs3918226 (NOS3) 10 with genome-wide significant blood pressure associations that are independent of the Exome Chip variants (r 2 = 0.007 for rs17428471 and rs6969780 and r 2 = 0.007 for rs3918226 and rs891511 in 1000 Genomes Project data). Variant rs2651899 in PRDM16 has been reported to be associated with migraine 36 , but this variant is not in linkage disequilibrium (LD) with the new blood pressure variant, rs2493292 (r 2 = 0.01 in 1000 Genomes Project data), suggesting predisposition to distinct vascular consequences for different variants in this locus. In addition, PRDM16 has been shown to have a critical role in vascular development 37 , adipocyte function in subcutaneous fat, and development of diabetes 38 . Finally, several variants in DOT1L were reported to be associated with cartilage thickness and hip osteoarthritis 39 .
The new blood pressure variant rs2302061, however, was not in LD with any of the previously identified signals at this locus 39 .
Together, the 31 newly identified single variants explain 0.7% and 1.3% of between-individual variation in SBP and DBP, respectively. The previously established and newly identified variants together explain 2.8% and 2.9% of phenotypic variation in SBP and DBP.
Gene-level analyses
We considered the possibility that an aggregation of rare or lowfrequency coding alleles in individual genes contributes to variation in blood pressure and specifically tested for effects of nonsynonymous, stop codon, and splicing coding variants with MAF <0.05 (T5 test) or MAF <0.01 (T1 test) using the seqMeta package. The standard burden test 40, 41 , which is sensitive in detecting association when all variants have effects on blood pressure in a concordant direction, identified an aggregation of rare and low-frequency coding alleles in PTPMT1 that contribute to higher odds of HTN (experiment-wide significance threshold P < 1 × 10 −6 ; Table 3 and Supplementary Table 8a) . Sequence kernel association testing (SKAT) 42 , which is designed to detect the effects of alleles that collectively contribute to higher and lower blood pressure, identified significant blood pressure associations for DBH (T1) and NPR1 (T5 ; Table 3 and Supplementary Table 8a) . Among additional EA individuals (up to 154,543 individuals) who were used for follow-up analysis, gene-based SKAT (with the RAREMETAL package) was performed for inverse-normaltransformed DBP, SBP, PP, and HTN (Online Methods). The genebased associations replicated in the follow-up samples at P < 0.05/3 ~0.017 for NPR1 (P = 4.4 × 10 −5 for SBP) and were marginally significant for PTPMT1 (P = 0.019 for HTN) and DBH (P = 0.053 for DBP) ( Supplementary Table 8b) .
Twenty-eight genes previously reported to be associated with monogenic blood pressure disorders 3 The discovery meta-analysis was performed in CHARGE+ Exome Chip BP Consortium samples (n = 146,562). The follow-up meta-analysis was performed with samples from the CHD Exome+ Consortium, ExomeBP Consortium, GoT2DGenes Consortium and T2D-GENES Consortium (n = 180,726). The 'combined', or joint, meta-analysis was performed with both discovery and follow-up samples (n = 327,288). Chr., chromosome; CA, coded allele; NCA, non-coded allele; CAF, coded allele frequency; SE, standard error; SYN, synonymous; IN, intronic; ITG, intergenic; ICBP discovery, the discovery sample for the International Consortium for Blood Pressure; NA, not available; IQ, imputation quality; r 2 /IQ, LD between the best proxy in ICBP and the one in the "dbSNP ID" column and imputation quality for the best proxy. Table 9) . Mutations in SLC12A1, encoding the Na-K-2Cl co-transporter, cause Bartter's syndrome, a Mendelian salt-wasting condition associated with hypotension 43 . The 26 variants in SLC12A1, however, did not overlap with the previously reported variants for Bartter's syndrome 43 . The 27 other genes associated with monogenic blood pressure disorders did not reach statistical significance in standard burden testing. Additionally, none of the 28 genes showed significant association with blood pressure using SKAT 42 (all P > 0.0006; Supplementary Table 9 ).
Inferred function of the identified blood pressure loci
We applied several computational strategies and conducted cis expression quantitative trait locus (cis-eQTL) analysis to infer biological functions associated with genes at the 31 significant single-variant blood pressure loci (see details in the Supplementary Note).
Disease and pathway enrichment analysis. We examined functional annotations derived from precompiled gene sets in GeneGo and literature-based inference in Literature Lab 44 . In GeneGo biological processes, the 31 new loci were enriched for cell signaling and development functions (for example, 'regulation of signaling' and 'regulation of growth') as compared with the largely cardiovascular functions (for example, 'negative regulation of (smooth) muscle contraction' and 'blood circulation') found for the 39 validated blood pressure loci (Supplementary Table 10 ). The new loci were also enriched for several conditions related to cardiovascular and metabolic disease (for example, 'myocardial ischemia' , 'congenital hyperinsulinism' , and 'acid-base imbalance'), whereas the validated loci were enriched for conditions more directly related to blood pressure or cardiovascular conditions Table 11 ) pathways and disease MeSH headings were enriched for insulin-related terms (for example, 'IGF-1' , 'type 2 diabetes' , and 'hyperinsulinism') for the new loci as compared to blood pressure-related terms (for example, 'cardiac muscle contraction') and cardiovascular electrophysiology (for example, 'antiarrhythmics') for the validated loci; both sets of loci were significant for 'heart development' . In the Literature Lab 44 anatomical annotations, the cardiovascular system (for example, 'myocardium' and 'heart ventricles') was highlighted for both the new and validated SNPs, while the validated SNPs were also associated with the renal system (for example, 'nephron' and 'urinary tract'). Almost no annotations for either GeneGo or Literature Lab 44 were unique to the set of combined new and validated loci with the exception of a few terms predominantly related to blood pressure or the renal system.
Protein-protein interaction analysis. Using NCBI protein-protein interaction (PPI) network resources (Supplementary Note),
a total of 399 genes were found to be connected to at least one of the 31 new blood pressure-associated genes (Supplementary Fig. 2) . Ordered on the basis of connectivity ('degree'; Supplementary Table 12), a measure that signifies a hub disposition in the PPI network, the top five blood pressure candidate genes were INSR, PABPC4, NOS3, IGFBP3, and DOT1L. On the basis of Google page rank, a connectivity measure that recognizes degree of connectivity while also emphasizing connections between highly connected nodes, the five top genes differed only by the replacement of IGFBP3 by PTPMT1 (Supplementary Table 12) .
ENCODE and Roadmap Epigenomics analyses. RegulomeDB 45 and HaploReg 46 evaluations of potential cis-regulatory functions identified rs8068318 (intronic to TBX2) as having the highest score among loci (or their LD proxies) that showed relatively strong evidence for a role in transcription (Supplementary Table 13 ). This SNP maps to an active TBX2 promoter histone mark in lung fibroblasts and DNase I hypersensitivity marks in seven cell types, while overlapping with five transcriptional regulatory motifs. TBX2 is a member of a highly conserved T-box family of transcription factors and has been implicated in cardiac developmental abnormalities 47, 48 and kidney function 26 .
Cis-eQTL analysis. The 31 newly identified blood pressure variants were queried for cis-eQTL association (Supplementary Table 14) in over 5,000 participants from the Framingham Heart Study (FHS), using microarray-based transcriptomic profiling of RNA from whole blood. A total of 720 SNP-transcript pairs were tested. Forty-three pairs (representing 17 variants) were significant at FDR < 10%, among which 8 variants were cis-eQTLs for multiple gene transcripts. For example, rs1953126 (near the 5′ UTR of PHF19) is a cis-eQTL for PHF19 and for multiple nearby genes, including C5, GSN, PSMD5, RAB14, FBXW2, and TRAF1. Query of publicly available eQTL databases via GRASP 49 and recent publications 50,51 based on profiling of whole blood or other tissue types [50] [51] [52] [53] [54] [55] [56] [57] yielded eQTL assignments that were concordant with the FHS findings for most variants listed in Supplementary Table 14 .
Effects of blood pressure-associated variants on clinical outcomes
We considered the aggregate effects of the blood pressure loci on blood pressure-related clinical outcomes using new Exome Chipbased results for coronary artery disease (CAD) and myocardial infarction, including 42,335 cases and 78,239 controls 58 , and for renal function measured by glomerular filtration rate (GFR) in up to 111,655 individuals. For 59 of the 70 (31 new and 39 validated) blood pressure-associated SNPs, the alleles that were associated with higher blood pressure were also associated with increased odds of CAD and myocardial infarction (Supplementary Tables 15 and 16 ), a highly significant concordance with the known influence of blood pressure on CAD and myocardial infarction (sign test, binomial P = 4.5 × 10 −9 ). Similarly, genetic risk scores (GRSs) constructed from the 70 blood pressure SNPs using weights derived from their effects on SBP, DBP, and MAP were highly significantly associated with CAD and myocardial infarction with odds ratios (per 1 mm Hg of SNP-based blood pressure) of 1.05 (P = 8.6 × 10 −44 ), 1.08 (P = 1.9 × 10 −41 ), and 1.06 (P = 1.1 × 10 −45 ), respectively (Supplementary Table 17 and Supplementary Note). Notably, the blood pressure-raising allele of one of the new low-frequency SNPs from single-variant analysis, rs111245230 in SVEP1, was by itself associated with increased CAD at genome-wide significance 58 . GRSs constructed solely from the rare and low-frequency variants at the three loci with significant genebased tests (DBH, NPR1, and PTPMT1) were significant for CAD and myocardial infarction using MAP-based weightings for DBH (P = 0.026) and HTN-based weightings for PTPMT1 (P = 0.003) with a non-significant concordant trend using MAP-based weightings for NPR1 (P = 0.13; Supplementary Table 18 ). By contrast, the blood pressure-raising alleles for only 39 of the 70 blood pressureassociated SNPs were associated with diminished kidney function (CKD) as reflected by lower GFR, a degree of concordance that was not significant (sign test, binomial P = 0.40). A similar lack of association was observed for the blood pressure GRS associations with GFR using weights for SBP (P = 0.18), DBP (P = 0.63), and MAP (P = 0.31).
DISCUSSION
Through a two-stage study design of discovery (n = 146,562) followed by external lookups (n = 180,726) and joint analysis (n = 327,288), we identified single-variant associations at 31 new loci and gene-based associations for three new genes (two of which overlapped with the single-variant loci) with blood pressure phenotypes. We also confirmed common variants at 39 previously reported blood pressureassociated loci, increasing the number of statistically significant loci in our study to 71 and extending the number of non-monogenic blood pressure-associated loci [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] to over 90. The sample size for the joint analysis in this study is far larger than that for any previous genetic study of blood pressure [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . This large increase in sample size is an important reason for the discovery of many new blood pressure loci and likely explains why some of the newly identified common loci were not discovered in previous blood pressure GWAS. In addition, direct genotyping of coding variants likely added incremental power over imputed genotypes and tagging SNPs that were the basis of previous GWAS, suggesting that new common variants will continue to be identified for blood pressure phenotypes using the same set or similar sets of samples with exome sequencing and whole-genome sequencing. Furthermore, phenotypic and possibly genetic heterogeneity (due to additional samples in this study), differences in analysis plans, and the play of chance may be additional explanations of why some of the common variants identified in this study were not identified in previous blood pressure GWAS. Fourteen of the new blood pressure variants identified in the present study reside in loci that were previously reported in GWAS to be associated with lipid levels 19 , immunological diseases [20] [21] [22] , and metabolic phenotypes [23] [24] [25] 29 (Table 2 and Supplementary Table 7) . Thirteen of the previously identified blood pressure variants were also linked to non-blood pressure traits or diseases (Supplementary Table 19 ). Considerable evidence has accumulated linking high blood pressure to insulin resistance, altered lipid levels, inflammation, and other features of the metabolic syndrome [59] [60] [61] [62] [63] [64] . Gene set enrichment, regulatory sequence variation, and PPI annotations of the new blood pressure loci implicate genes that contribute to cardiac structure and function as well as insulin signaling and type 2 diabetes. In addition, among the previously reported blood pressure-associated genes that were confirmed in our study, ATXN2, GRB14, HECTD4, PTPN11, and SLC39A8 (Supplementary Table 3 ) have been proposed as candidate genes for metabolic syndrome on the basis of their associations with metabolic traits and inflammatory biomarkers 64 .
The NPR1 gene was associated with blood pressure in both singlevariant and gene-based tests. This gene encodes the receptor for atrial and B-type natriuretic peptides, which regulate blood volume and pressure 17, 18 . The functional consequences of the p.Glu967Lys amino acid substitution that is encoded by rs35479618 (the significant NPR1 SNP in single-variant analysis) are unknown, but the change results in opposite charge and a large difference in side chain volume, and it is predicted to be possibly damaging (score = 0.513) by PolyPhen-2 (ref. 65) . The effects of the 13 rare variants and 1 low-frequency variant in NPR1 varied in direction, explaining why gene-based testing was significant using SKAT 42 , which is sensitive to effects raising and lowering blood pressure, but not in burden testing 40, 41 , which requires a consistent direction of effect on blood pressure ( Fig. 2 and Supplementary Fig. 3 ). Of note, Npr1-knockout mice have HTN, cardiac hypertrophy, and sudden death phenotypes 17, 18, 66 , and mice with only one copy of the Npr1 gene have salt-sensitive HTN as compared to wild-type mice 17 . Future studies are warranted to determine whether humans carrying the rare blood pressure-increasing alleles of NPR1 also have salt-sensitive HTN. We have previously demonstrated that common variation that raises atrial natriuretic peptide levels lowers blood pressure 13 , suggesting the potential for blood pressurelowering strategies that target the interaction of natriuretic peptide with natriuretic peptide receptors. Similarly, molecular mimicking of the action of blood pressure-lowering alleles in NPR1 may be worth exploring as a novel blood pressure treatment.
Both single-variant and gene-based (T1) analyses in stage 1 identified DBH as a blood pressure-associated gene (Fig. 3) . DBH encodes the enzyme dopamine β-hydroxylase, which catalyzes the transformation of dopamine into norepinephrine. Both dopamine and norepinephrine act on the sympathetic nervous system, influencing a variety of complex traits, including blood pressure. Impaired dopamine β-hydroxylase activity has been identified in individuals with severe autonomic failure, including orthostatic hypotension 67, 68 , and mutation of DBH has been identified in two individuals with autonomic dysfunction 69 . The rare minor allele of rs3025380, encoding the p.Gly88Ala nonsynonymous substitution, was associated with a comparatively large reduction of 1.81 mm Hg in MAP even though the amino acid change is predicted to be remote from the active site 70 . Inhibition of dopamine β-hydroxylase has long been considered a potential target for antihypertensive therapy 71 , but these efforts have been undermined because of the broad involvement of catecholamines in a variety of critical biological processes 72, 73 and the potential for undesirable side effects.
The remaining significant gene in gene-based testing was PTPMT1, which encodes mitochondrial protein tyrosine phosphatase 1. Knockdown of Ptpmt1 expression in a rat pancreatic insulinoma cell line was found to enhance ATP production and insulin secretion 74 , an observation that is closely aligned with the insulin and cardiometabolic regulatory features of many of the new blood pressure loci identified in this study. In addition, targeted burden testing of uncommon and rare variants in genes that underlie monogenic blood pressure disorders identified a significant blood pressure association with SLC12A1, the Na-K-2Cl co-transporter that is well established to harbor rare mutations that cause Bartter's syndrome, a salt-wasting condition associated with hypotension 43 . 
A r t i c l e s
The Exome Chip array was designed to aid in the search for rare functional variants with large effect sizes. This study did not, however, identify any rare variants associated with blood pressure phenotypes through single-variant analyses, suggesting that rare variants with large effects on blood pressure are an uncommon occurrence. Even with the current sample size, this study was not adequately powered to identify rare variants with only modest effect sizes (Online Methods). Within the predominant class of variants studied (low-frequency and rare nonsynonymous SNPs), there may not be a large enough number of variants or effects of sufficient size to account for a substantial proportion of the remaining missing heritability of blood pressure. Nevertheless, this study greatly extends the number of known blood pressure-associated loci and moreover demonstrates their potential relevance to cardiovascular disease. The discovery of a total of 32 new blood pressure-associated loci (31 from single-variant tests, 1 from gene-based tests) and their overlap with other disease-related phenotypes suggest common etiologies of blood pressure and metabolic risk factors and an opportunity to identify therapies that more broadly influence HTN in the context of cardiometabolic risk. elias salfati 60 , tamara B Harris 61 , lenore J launer 62 , marcus dörr 11,63 , stephan B Felix 11,63 , Rainer Rettig 11 meta-analysis was conducted in EA-only samples. The inverse-varianceweighted method was used in meta-analysis of the discovery and follow-up results for DBP, PP, and SBP. Because the follow-up samples provided only z scores and sample sizes for HTN, the optimally weighted z-score method 79 was used in meta-analysis of HTN. The threshold of P ≤ 3.4 × 10 −7 was required for significance in meta-analyses of the discovery and follow-up samples.
URLs
Functional inference. We applied several computational strategies to infer biological functions associated with candidate genes from the 31 new loci reaching P < 3.4 × 10 −7 ( Table 1 ) and 39 validated loci (Supplementary Table 3) . (i) To test whether the SNPs in Table 1 and Supplementary Table 3 were significantly enriched among prespecified gene sets defined in pathways or by shared roles in particular diseases or biological processes, we performed gene pathway, disease, and Gene Ontology (GO) enrichment analysis using GeneGo software and Literature Lab 44 data mining of the literature (Supplementary Note).
(ii) To investigate whether the coding and noncoding variants listed in Table 1 might influence transcriptional regulation, we compared blood pressure candidate SNPs with ENCODE and Roadmap Epigenomics regulome features summarized for mainly cis-regulatory function in HaploReg 46 and RegulomeDB 45 . The inclusion of coding variants in this analysis was justified by previous research showing that transcriptional regulation can be influenced by both noncoding and coding variations; a recent publication has shown that ~15% of human codons simultaneously specify both amino acids and transcription factor recognition sites 80 . (iii) To identify genes that encode proteins especially connected with other proteins and therefore inferred to be important, we performed PPI network analysis on the SNPs in Table 1 . The PPI network was constructed using NCBI PPI database information, which sources information from the HPRD, BIND, BioGRID, and EcoCys databases. By design, 2% of the Exome Chip variants were identified from previous GWAS. To investigate whether these previous GWAS SNPs might artificially increase the extent of GeneGo enrichment in known functional classes, we performed GeneGo enrichment analysis on ten randomly selected sets of genes from the Exome Chip (with replacement) with the size of new and previous blood pressure candidates discovered. None of these random sets showed gene set enrichment with significance comparable to the enrichment for the blood pressure SNPs.
To further assess putative functionality for the new loci, we performed cis-eQTL analysis between each of the newly identified variants and gene expression within 1 Mb flanking that variant in peripheral whole-blood samples from ~5,000 individuals from FHS. Statistical significance in the FHS expression data was evaluated at FDR < 10% for newly identified variants 81 . We also searched for cis associations between new variants and gene transcripts within 1 Mb flanking the lead SNP based on databases of previously published eQTL analyses at FDR < 10% (refs. 50,82) .
